Business Context and Reporting Period
Company: 60 Degrees Pharmaceuticals, Inc. (SXTP)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal Year Ended December 31, 2025
Business Overview: A specialty pharmaceutical company focused on infectious diseases. Its primary commercial product is Arakoda (tafenoquine), approved for malaria prevention. The company is actively developing new indications for tafenoquine, specifically for the treatment of Babesiosis (a tick-borne disease), and exploring other candidates like Celgosivir and Australian Chestnut Extract.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Product Revenue (Net of discounts/rebates) | $1,005,471 | $607,574 |
| Research Revenue | $403,624 | $73,771 |
| Total Net Revenue | $1,409,095 | $681,345 |
| Gross Profit | $223,776 | $222,809 |
| Gross Margin | 22.26% | 36.67% |
| Net Loss (Attributed to 60P) | $(7,365,158) | $(7,947,107) |
| Cash and Cash Equivalents (Dec 31, 2025) | $1,510,065 | $1,659,353 |
| Total Debt (SBA EIDL) | $152,775 | $155,891 |
Note: The company reported a net loss for the year, though the loss narrowed slightly compared to 2024. Gross margin declined due to significant inventory write-offs ($445,181) related to expiring stock during a supply chain transition.
Material Changes vs. Prior Period
- Revenue Growth: Product revenue increased 65.5% year-over-year, driven by rising sales volume (12% increase in units) and price adjustments, despite a temporary shortage of 16-count boxes in mid-2025.
- Research Revenue Surge: Research revenue jumped 447% to $403,624, primarily due to a new contract with the U.S. Army Medical Materiel Development Activity (USAMMDA) for supply chain upgrades and a contract with the University of Kentucky.
- Expense Reduction: Research and Development (R&D) expenses decreased 57.8% to $2.1 million. This was largely due to the absence of a $3.2 million non-cash share-based payment charge recognized in 2024 related to vendor services.
- Capital Raises: The company executed multiple equity financings in 2025, including a July registered direct offering (net proceeds ~$4.3M) and ATM offerings, to bolster liquidity.
- Reverse Stock Splits: The company effectuated three reverse stock splits in 2024 and 2025 (1:12, 1:5, and 1:4) to maintain Nasdaq listing compliance. All share data in this report is retroactively adjusted.
Guidance, Outlook, and Risks
Outlook and Strategy
- Babesiosis Development: The company is advancing three clinical trials for tafenoquine in Babesiosis. Trial 1 (hospitalized patients) has enrolled 19 patients; Trial 2 (expanded access) has cured 3 patients; Trial 3 (chronic fatigue) has enrolled 3 patients. Results are expected in Q3 2026.
- Commercialization: A promotional pilot for Arakoda in the U.S. is underway, utilizing virtual sales representatives and co-pay programs to increase awareness and trial usage.
- Liquidity: Management estimates sufficient funds to remain viable through September 30, 2026, assuming no additional capital raises. Subsequent events (March 2026) indicate additional ATM sales generated ~$2.5M in net proceeds.
Risks and Contingencies
- Going Concern: Auditors have expressed substantial doubt about the company's ability to continue as a going concern due to recurring losses and the need for additional financing.
- Internal Controls: Management identified material weaknesses in internal control over financial reporting, including inadequate policy design, lack of documentation, and segregation of duties issues. Remediation is expected in H1 2026.
- Regulatory: The company received a Nasdaq delisting notice in January 2026 for failing to maintain a $1.00 minimum bid price but regained compliance in February 2026.
- Supply Chain: The company relies on a sole vendor for the active pharmaceutical ingredient (API) for Arakoda. Disruptions could halt production.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the "September 2026" liquidity estimate given the high burn rate and recent capital raises.
- Inventory Valuation: Review the $445k inventory write-off and the remaining inventory balance ($657k) to assess the risk of future expirations.
- Clinical Trial Progress: Monitor enrollment rates and interim analysis results for the Babesiosis trials (NCT06207370, NCT06478641, NCT06656351) scheduled for 2026.
- Internal Control Remediation: Confirm the timeline and success of remediation efforts for the identified material weaknesses in financial reporting.
- Derivative Liability: Track the fair value of the $10M contingent milestone payment to Knight Therapeutics, which fluctuates based on the probability of a sale or change of control.